Recently, Dr. Hu Junyuan (formerly known as Hu Xiang), Chairman of Shenzhen Beike Biotechnology Co., Ltd., was named a national-level leading talent of Shenzhen.
Talent is the foremost resource for economic and social development, and the most active and dynamic factor in innovation. Practice since Shenzhen's reform and opening up has shown again and again that focusing on talent is focusing on development; strengthening talent is strengthening capability. Without an advantage in talent, there can be no advantage in development, innovation or industry.
High-level talent plays an important supporting role in driving Shenzhen's economic and social development. The municipal government invests no less than RMB 1 billion every year to cultivate and attract high-level talent and teams from China and abroad – evidence of the great importance Shenzhen places on talent.
Shenzhen's high-level talent is divided into national-level leading talent, local-level leading talent, reserve-level talent and overseas Class A, B and C talent. Hu Junyuan, Chairman of Shenzhen Beike Biotechnology Co., Ltd., has now been named a national-level leading talent of Shenzhen.
Dr. Hu Junyuan, Chairman of Beike Biotech, holds a PhD in biochemistry and molecular biology from the University of Gothenburg and Chalmers University of Technology in Sweden, completed postdoctoral research at the University of British Columbia in Canada, and is a Visiting Professor in the Department of Surgery at The Chinese University of Hong Kong and a Visiting Professor at the Shanghai Institute of Cardiovascular Diseases. He currently serves as Director of the Shenzhen Stem Cell Engineering Technology Research and Development Center, Vice Chair of the National Stem Cell and Regenerative Medicine Industry Technology Innovation Strategic Alliance, Vice Chair of the China Strategy and Management Research Society, member of the International Advisory Committee of UNICEF, Executive Chair of the Xiongan International Health Forum, and Chairman of Shenzhen Beike Biotechnology Co., Ltd. He holds multiple international and domestic patents in the clinical translation of adult stem cells.
Further reading:
In January 2020, the research outcome "Key Technical Innovation and Clinical Application of Allogeneic Mesenchymal Stem Cells in Treating Refractory Lupus Erythematosus", led by Dr. Hu Junyuan and his team at Beike Biotech, received the 2019 National Technological Invention Award.
In June 2020, the new drug clinical registration application for Beike Biotech's independently developed product "Human Umbilical Cord Mesenchymal Stem Cells for Injection for the Treatment of Refractory Systemic Lupus Erythematosus" was officially accepted by the Center for Drug Evaluation of the National Medical Products Administration. The acceptance number is CXSL2000128. This stem cell new drug is China's first stem cell product targeting refractory systemic lupus erythematosus.
